Moderna Inc. announced that phase 3 trials will begin for its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, which is being tested in adults who are 60 years of age and older.
The mRNA-1345 vaccine is based on the same messenger RNA (mRNA) technology used in the company’s COVID-19 vaccine (Spikevax). The mRNA-1345 vaccine encodes for a prefusion F glycoprotein, which elicits a high neutralizing antibody response.
The decision follows endorsement of preliminary phase 2